Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Blood (2024) 144 (2): 201–205.

https://doi.org/10.1182/blood.2023022295

Published: 2024

Includes: Supplemental data

Journal Articles

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Blood (2024) 143 (8): 734–737.

https://doi.org/10.1182/blood.2023022937

Published: 2024

Journal Articles

Monitoring of Systemic Light-Chain Amyloidosis Patients Using Mass Spectrometry (M-inSight) in Serum

Zarouki Mouktadi, Paul-Henri Diemont, Luciano Di Stefano, Vincent Bonifay, Sebastien Bender, Virginie Pascal, Christophe Sirac, Murielle Roussel, Caroline Rougé Dubroc, Pierre Sonigo

Blood (2023) 142 (Supplement 1): 3413.

https://doi.org/10.1182/blood-2023-181562

Published: 2023

Journal Articles

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Murielle Roussel, Peter Mollee, Antoine Huart, Hasib Sidiqi, Noemi Horvath, Lionel Karlin, Caroline Jacquet, Pierre Morel, Cecile Leyronnas, Sebastien Bender, Frank Bridoux, Arnaud Jaccard, Simon D. Gibbs

Blood (2022) 140 (Supplement 1): 12618–12620.

https://doi.org/10.1182/blood-2022-166337

Published: 2022

Journal Articles

Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network

Murielle Roussel, Michelle Pirotte, Ornella Rizzo, Kentin Queru, Thomas Chalopin, Olivier Decaux, Estelle Desport, Frank Bridoux, Arnaud Jaccard

Blood (2022) 140 (Supplement 1): 10086–10087.

https://doi.org/10.1182/blood-2022-166224

Published: 2022

Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Blood (2022) 140 (Supplement 1): 1142–1145.

https://doi.org/10.1182/blood-2022-165524

Published: 2022

Journal Articles

Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study

Murielle Roussel, Nathalie Texier, Raphaël Germain, Sandhya Sapra, Prani Paka, Naima Kerbouche, Xavier Colin, Xavier Leleu

Blood (2022) 140 (Supplement 1): 4261–4263.

https://doi.org/10.1182/blood-2022-156035

Published: 2022

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Blood (2021) 138 (25): 2686–2695.

https://doi.org/10.1182/blood.2021011285

Published: 2021

Includes: Supplemental data

Journal Articles

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal

Blood (2021) 138 (Supplement 1): 464.

https://doi.org/10.1182/blood-2021-146040

Published: 2021

Journal Articles

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Blood (2021) 138 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2021-152136

Published: 2021

Journal Articles

A Transgenic Mouse Model of Cardiac AL Amyloidosis

Gemma Martinez-Rivas, Maria Ayala, Sebastien Bender, Murielle Roussel, Arnaud Jaccard, Frank Bridoux, Christophe Sirac

Blood (2021) 138 (Supplement 1): 1592.

https://doi.org/10.1182/blood-2021-146782

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Blood (2020) 135 (18): 1531–1540.

https://doi.org/10.1182/blood.2019004369

Published: 2020

Includes: Supplemental data

Journal Articles

Crowded bone marrow plasma cells

Jill Corre, Murielle Roussel

Blood (2020) 135 (1): 79.

https://doi.org/10.1182/blood.2019003098

Published: 2020

Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD

Blood (2019) 134 (Supplement_1): 1891.

https://doi.org/10.1182/blood-2019-127076

Published: 2019

Journal Articles

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Elena Zamagni, MD, Sujith Dhanasiri, Adam Moore, Arun Ghale, Murielle Roussel, MD

Blood (2019) 134 (Supplement_1): 4772.

https://doi.org/10.1182/blood-2019-123629

Published: 2019

Journal Articles

Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Murielle Roussel, MD, Benjamin Hebraud, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Thierry Facon, MD, Eileen Boyle, MD PhD, Cyrille Touzeau, MD PhD, Brigitte Pegourie, MD, Aurore Perrot, MD PhD, Anne-Marie Stoppa, MD, Jean-Pierre Marolleau, MD PhD, Philippe Moreau, MD, Herve Avet-Loiseau, MD PhD, Laure Devlamynck, Valerie Lauwers-Cances, MD, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3159.

https://doi.org/10.1182/blood-2019-123184

Published: 2019

Journal Articles

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Blood (2018) 132 (24): 2555–2563.

https://doi.org/10.1182/blood-2018-07-863829

Published: 2018

Includes: Supplemental data

Journal Articles

The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, Aurore Perrot, Denis Caillot, Margaret Macro, Bertrand Arnulf, Karim Belhadj, Laurent Garderet, Thierry Facon, Shien Guo, Arman Altincatal, Sujith Dhanasiri, Xavier Leleu, MD PhD, Philippe Moreau, Michel Attal

Blood (2018) 132 (Supplement 1): 716.

https://doi.org/10.1182/blood-2018-99-111477

Published: 2018

NARROW

RAS/RAF landscape in monoclonal plasma cell conditions

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Monitoring of Systemic Light-Chain Amyloidosis Patients Using Mass Spectrometry (M-inSight) in Serum

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

A Transgenic Mouse Model of Cardiac AL Amyloidosis

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Crowded bone marrow plasma cells

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only